This study shows that apoA-I may be an alternative strategy to improve the biocompatibility of stents. 
SUMMARY
Even the most advanced drug-eluting stents evoke unresolved issues, including chronic inflammation, late thrombosis, and neoatherosclerosis. This highlights the need for novel strategies that improve stent biocompatibility. Our studies show that apolipoprotein A-I (apoA-I) reduces in-stent restenosis and platelet activation, and enhances endothelialization. 
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ApoA-I Improves Stent Biocompatibility thrombosis, and re-endothelialization following stent deployment. IMMUNOHISTOCHEMISTRY. Resin-embedded sections were subjected to antigen retrieval using a Tris-EDTA buffer (pH 9.0). Vessels were stained for SMC a-actin arteries from PBS-infused mice. These effects were
METHODS
ApoA-I Improves Stent Biocompatibility independent of changes in lipids (total, lowdensity lipoprotein, and HDL); however, human apoA-I was detected in the plasma of apoA-Iinfused mice but not PBS-infused mice (Supplemental Table 1 ). Vanags et al.
ApoA-I CHANGES THE CELLULAR
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ApoA-I Improves Stent Biocompatibility Table 2 ). Inadequate re-endothelialization is associated with neointimal expansion and an increased risk of thrombosis after PCI. We found that apoA-I increased aortic Vanags et al.
DISCUSSION
ApoA-I Improves Stent Biocompatibility may be a promising therapy that further reduces stent thrombosis rates or for those patients with dualantiplatelet therapy intolerance. We also found that, although not significant, the rate of thrombosis was lower post-stenting in mice infused with apoA-I. This is interesting because the stented mice had aspirin supplemented into their drinking water, which would have substantially reduce platelet activation in both groups, making a benefit from apoA-I difficult to achieve. Our findings are consistent with an epidemiological study in which low HDL levels were found to be a predictor of major cardiac events including death due to in-stent thrombosis in patients receiving DES (24) . Furthermore, these observations are in accordance with studies in humans that show infusions of rHDL reduced p-selectin in diabetic patients (12).
Our alternate-day infusions of apoA-I caused transient peaks in circulating apoA-I and HDL-cholesterol concentrations. We have shown that for apoA-I, the peak occurs 2 h after infusion (69.4 mmol/l) (25) . 
